Eastern Equine Encephalitis Virus Complex: Human Disease, Diagnosis and Treatment Authors: Mohammed Umar, Evan P. Williams, Gabriel Correa Quitete Schaller Chagas, Anuj Singh, Katarina Rueda, Colleen B. Jonsson Published: 2026 ABSTRACT The Eastern equine encephalitis virus (EEEV) complex comprises mosquito-borne neurotropic alphaviruses maintained in nature by mosquitoes. Although rare, human infections caused by these viruses can lead to febrile illness that may progress to severe encephalitis, for which there are no vaccines for prevention and no specific therapeutics for treatment. Moreover, a high percentage of human cases show long-term neurological sequelae. Here, we review the literature on cases, diagnosis, and management. Current gaps in clinical care include an urgent need to develop rapid diagnostic tests, new therapeutics, and vaccines. 1. Introduction The Eastern equine encephalitis virus (EEEV) complex comprises mosquito-borne viruses with a single-stranded, positive-sense RNA genome in the genus Alphavirus, family Togaviridae [1,2]. The EEEV (lineage I) is maintained in nature in enzootic cycles between Culiseta melanura mosquitoes and passerine birds that serve as amplifying hosts in hardwood swamps in the eastern and southeastern coastal regions of the United States of America (USA) and Mexico [1,3]. Importantly, C. melanura feeds entirely on birds, meaning that transmission of the virus to humans and other dead-end mammalian hosts such as horses depends on “bridge” mosquitoes—including Aedes, Coquillettidia, and Culex species—that feed on both birds and mammals. The Central and South American EEEV complex lineages II-IV are distinct from EEEV and were reclassified as the Madariaga virus (MADV) [4]. While the details for the vector(s) for MADV remain under investigation, studies suggest that Culex (Mel.) pedroi and Culex (Mel.) taeniopus may serve as potential vectors [5,6]. MADV has been detected in Oryzomys sp., Didelphis marsupialis (common opossum), lizards, and bats [7,8,9]. Human infection with EEEV and MADV occurs as a result of bites from infected mosquitoes [1,2] (Figure 1). EEEV is now recognized as one of the deadliest mosquito-borne diseases in the USA, with annual fatality rates up to 75% among individuals who develop neurological symptoms and disease [10,11,12]. Sadly, a majority of patients with EEEV-associated neurologic disease develop long-term sequelae, including seizures, altered mental status, somnolence, intellectual disability with cognitive and motor impairments [2,13,14]. These complications often lead to lifelong healthcare challenges and substantial costs, underscoring the serious impact of the disease on both public health and quality of life in the USA [11,15,16,17,18]. In Latin America, MADV is the primary agent responsible for equine outbreaks since the 1930s, but it has only rarely been linked to human disease before the outbreak in 2010 in Panama [19,20]. In this first recognized human outbreak of MADV, 53% of the cases were children and progressed to neurological disease [20]. In contrast to EEEV cases, we have limited information on neurological sequelae, and the reported fatalities are low [20,21,22,23,24,25]. Because the areas in Latin America that are endemic for MADV and the other viruses circulating, i.e., DENV, ZIKV, and CHIKV, are rural, the incidence is likely underreported [26]. Despite recent advances in research on these viruses and their diseases, supportive care remains the mainstay of management for EEEV and MADV [26,27]. Follow-up studies of survivors suggest potential for cognitive and motor recovery, with improvement seen in about 40% of patients overall and up to 75% of those with severe deficits. However, the underlying causes of these persistent sequelae remain unclear for EEEV and MADV [18,26]. The lack of commercially available rapid diagnostic tests to identify EEEV or MADV infection forces clinicians to rely on detecting viral antigen or culturing viruses from cerebrospinal fluid (CSF). This review focuses on current clinical findings from confirmed EEEV and MADV cases (Table 1), diagnostic approaches, management, and treatment, as well as limitations in these areas and potential directions for future research. 2. Viral Classification and Epidemiology As mentioned previously, the species Alphavirus eastern (EEEV) occurs in North America and the Caribbean, while lineages 2, 3, and 4, species Alphavirus madariaga (MADV), circulate in Central and South America (Table 2) [52]. The genomes of the EEEV strains are highly conserved in the USA and Mexico, whereas the genomes of the Central and South American MADV strains tend to exhibit greater genetic diversity [2,4]. Because of this genetic diversity of available full-length genome sequences, Central and South American EEEV strains formerly known as South American Eastern equine encephalitis viruses were reclassified as MADV in 2010 [4]. The virus is named after the region where the virus was first isolated in 1930, the General Madariaga Partido, Buenos Aires Province, Argentina [64]. It is important to note that before the reclassification, the literature from Central and South America that references EEEV actually refers to MADV. Confirmed cases of EEEV and MADV cases span all age groups, from 4-week-old to over 70 years old, and both sexes are represented (Table 1) [48,50]. Notably, of the 355 cases reported in the USA since 1938, the apparent average mortality is 45%, with a range of 0 to 69% by year (Table 2). An average of 11 EEEV cases are reported each year in the USA according to the CDC. Based on the available information on MADV cases, we estimate an average mortality rate of ~9% (Table 1 and Table 2). A review of the reported case studies of EEEV (Table 1) reveals that most patients were exposed to mosquitoes in rural areas while hiking, camping, hunting, or living or working in forested or bog areas [37,45,47,49,51,55,57]. Similarly, MADV cases are associated with activities in rural areas, such as agriculture, farming, cattle ranching, andfishing, inforest and swamp areas, and in housing conditions that favor mosquito breeding; for example, see [9,20,21,32,34] and other references for MADV cases in Table 1. Since the EEE disease was first recognized in a cluster of 34 cases in the fall of 1938 in southeastern Massachusetts, cases typically occur from July through October [1,15,20,49]. The age distribution of the 34 EEEV cases reported in 1938 who were hospitalized was between the ages of one month and ten years of age, and 65% of them eventually died [65]. Additional cases in Massachusetts were not noted until 1955 and 1956, when a small cluster of four and 12 human cases were identified, respectively [30]. Since that time, EEEV cases in the USA have occurred along the Atlantic and Gulf Coasts, including New Hampshire, Florida, Louisiana, Alabama, and Texas [12,30]. Cases associated with EEEV were first reported in New Jersey in 1959, with 32 laboratory-confirmed cases over eight weeks [16,33]. More recently, in 2019, more than 70 years after the first cases reported in 1938, 38 cases with 12 deaths were reported from persons living mostly in Massachusetts and Michigan [66,67]. Interestingly, while cases in the northeastern USA tend to be seasonal—between July and October—Florida experiences cases year-round [68]. MADV had been consistently detected in equines and mosquitoes but had been reported in only three human cases in Central and South America before the 2010 outbreak in Panama. Of these three cases reported before 2010, one fatal MADV case was reported in 1955 in Brazil, and two cases, one fatal, were reported in Trinidad and Tobago in 1970 [32,34]. In the 2010 Panamanian outbreak, there were seven cases confirmed for MADV, and all survived [20]. Human and equine MADV cases began in May at the start of the rainy season. In a follow-up study of cases five years after the 2010 Panamanian outbreak, high rates of self-reported memory loss, fatigue, and a significant increase in the incidence of seizures were reported. Remarkably, none of these people had any neurological symptoms in 2010 [20]. Hence, despite the low mortality associated with the 2010 outbreak (<3%), this study suggests that even mild cases of MADV represent a serious and prolonged risk to health [21]. Lastly, cross-sectional serological studies in Panama, Peru, and Brazil report seropositivity rates to MADV ranging from 1 to 19% in human populations [9,20,69]. The high seroprevalence in Panama suggests subclinical infections in this region. A cross-sectional study of blood donors living in endemic areas conducted in 2019–2020 in the USA reported a seroprevalence to EEEV of 1.62% in one county in Massachusetts [70]. The only other study was conducted in New Jersey following an outbreak in 1959, where seroprevalence ranged from 0.9 to 6.2% [33]. 3. Viral Life Cycle Alphaviruses are enveloped spherical particles of approximately 70 nm with a positive-sense, single-stranded genome enclosed in an icosahedral nucleocapsid. The approximately 11,700-nucleotide genome organization and architecture are highly conserved among alphaviruses, with two open reading frames (ORFs) [71]. The first ORF encodes the nonstructural proteins (nsP1, nsP2, nsP3, and nsP4), which are essential for the assembly of the replication complex and its activity [72]. The second ORF encodes for structural proteins: the capsid, E3, E2, 6K, and E1 [73]. The proteins nsP1, nsP2, nsP3, and nsP4 support RNA synthesis [74,75]. nsP1 mediates positive-sense RNA capping of the viral genome via methyltransferase and guanylyltransferase activities [72,76]. The nsP2 provides helicase, NTPase, RTPase, and protease activities essential for RNA replication. The helicase and NTPase unwind RNA structures in concert with nsP4, while the RTPase generates the 5′-diphosphate ends required for nsP1-mediated capping [77]. The C-terminal domain of nsP2 functions as a protease that cleaves the nonstructural polyprotein in cis or trans, generating distinct replication activities during the viral life cycle [78]. While nsP3 plays a role in regulating RNA synthesis, it has not yet been visualized within the replication complex [79,80]. The RNA-dependent RNA polymerase activity is mapped to nsP4 [81,82]. The E1 and E2 proteins mediate entry by interacting with the very low-density lipoprotein receptor (VLDLR) and/or apolipoprotein E receptor 2 [73,83,84]. Various studies have shown that EEEV neurovirulence, its heparan sulfate binding phenotype, and lack of lymphotrophism are linked to three basic lysine residues, Lys71, Lys74, and Lys77 (‘‘Lys-triad’’), on the E2 ectodomain [2,85,86]. Positively charged binding sites on the EEEV E2 glycoprotein enhance interactions between EEEV-heparan sulfate and EEEV-protein receptor, suggesting these poly-functional sites increase infection in vitro and drive pathogenesis in vivo [83]. 4. Clinical Manifestations In general, clinical symptoms following infection with MADV or EEEV during the prodromal phase of illness (Figure 2A) begin abruptly with headache, high fever, and other symptoms suggestive of central nervous system involvement, such as vomiting, drowsiness or confusion, and seizures appearing within 24–48 h [10,65]. On hospitalization, patients exhibit five key symptoms that can last for over 15 days: fever, headache, nausea or vomiting, seizures, and altered mental state (confusion) [10]. Fever ranges from 38.1 °C to 40.4 °C (101 °F to 105 °F) [41,52]. In addition to fever and headaches, nausea or vomiting are some of the most common symptoms of EEEV infection [35,39,57]. EEE patients may also present on hospitalization with neck stiffness, myalgia, arthralgia, orthopnea, ataxia, malaise, facial paresthesia, and fatigue [10,35,42,49] such that the prodromal and encephalic stages of disease show overlap (Figure 2A). Short-term neurological sequelae are very common in patients, and up to 75% of EEEV survivors report long-term neurological sequelae, which include cognitive, sensory, and motor deficits (Figure 2A) [87]. Two key manifestations of encephalitis are altered mental status (i.e., consciousness, memory, recognition) and seizures (see, for example, [45,57]). Tonic–clonic seizures, recognized by loss of consciousness and violent muscle spasms, are caused by excessive, hypersynchronous neuronal discharge, possibly due to inflammation of the brain in response to EEEV infection [88]. As compared to EEE cases, the Panamanian MADV patients had a higher rate of seizures progressing to status epilepticus, which is when the patient does not regain consciousness between seizures [11,20]. EEG testing of EEEV patients shows slowing, rhythmic delta activity, and disorganization of the background EEG signal [10,35,49,89]. EEEV cases have abnormalities in the basal ganglia, thalami, cortical areas, and the brainstem as revealed by magnetic resonance imaging (MRI) and/or computed tomography (CT) [10,11,39,41,57]. Reporting on MRI is limited for MADV, but a review of four MADV case findings from the 2010 outbreak in Panama suggested that the basal ganglia and thalamic lesions, which are the predominant findings in EEE cases, were not as evident, and that other regions, such as the temporal lobes, were also involved [20,43]. In fatal cases in which an autopsy is conducted, gross examination of the brain reveals edema, leptomeningeal vascular congestion, hemorrhage, and encephalomacia [10]. The leptomeninges are membranes (pia mater and arachnoid mater) that surround the brain and spinal cord. Symptoms associated with blood accumulation in the leptomeninges include nausea, headache, and vomiting. Encephalomalacia refers to softening or loss of brain tissue, causing drowsiness and headache, and leading to permanent brain damage. Microscopic pathology includes vascular components (e.g., perivascular cuffing, small-vessel thrombosis), focal neuronal necrosis, neuronophagia, and glial proliferation and glial nodules. 5. Diagnostics Early diagnosis of EEEV or MADV infections is challenging because the initial clinical symptoms are nonspecific and overlap with those of many other illnesses. The diagnosis of infection with these viruses is further hampered by the lack of widely available virus-specific diagnostic tests. The Centers for Disease Control and Prevention (CDC) has made extensive efforts since 1955 to establish diagnostic criteria for arboviruses, including EEEV [65,90] which includes virus isolation, the presence of viral antigen, or identification of IgM antibody to EEEV. Generally, blood and CSF are evaluated in microbiology laboratories for a wide range of bacterial and viral pathogens when patient infection is suspected [91]. In addition to microbiological testing, other diagnostic tests, such as blood and CSF laboratory tests, neurological imaging, and electroencephalograms (EEG), help refine the diagnosis and define disease status and progression. Each of these is reviewed in the following table (Table 3). 5.1. Confirmatory Microbiology According to the CDC’s surveillance case definition for EEEV [92], a case is considered confirmed if it fulfils any one of the following: (a) the isolation of infectious virus or identification of specific viral antigen or nucleic acid from bodily fluids, tissues, or CSF; (b) there is a fourfold or greater increase in virus-specific quantitative antibody titers in paired sera; or (c) there are virus-specific IgM antibodies in serum with confirmatory virus-specific neutralizing antibodies in the same or a later specimen. A case is considered probable if serum IgM capture ELISA is positive or if a single serum sample shows high antibody titers by hemagglutination-inhibition, complement fixation, immunofluorescence, or plaque-reduction neutralization test (PRNT) [10,35,40,90]. Virus isolation is performed by amplifying the virus in mosquitoes (e.g., C6/36) or mammalian (e.g., Vero) cell lines, followed by the detection of virus antigen using RT-PCR or virus-specific serological tests [27]. Isolation of viruses from CSF or brain tissue has been successful; hence, serological testing remains the primary approach for diagnosing EEEV. In general, IgM antibodies to EEEV and MADV can be detected in patients’ sera and CSF during the early phases of disease (Table 1). IgM antibodies have been observed as early as 1 day after symptom onset but are typically detectable within the first week [26,42,52,93]. In CSF, IgM antibodies have been reported as early as day 9 after symptom onset [94]. However, IgM antibodies can persist for an extended period (2-3 months) post-infection, so positive IgM results may represent past rather than acute infection and require additional confirmatory evidence, such as documented seroconversion in paired sera, to establish recent infection as the cause of the current illness [93]. Serological testing in immunocompromised individuals may yield false-negative results for IgM antibodies. Several case reports have documented delayed or negative serological results in patients receiving immunosuppressive therapies, which were confirmed by PCR or next-generation sequencing (NGS) [51,52,62]. In the USA, state or local health departments are contacted to arrange serologic testing in some state health departments (i.e., NYSDOH Wadsworth Center’s Laboratory of Viral Diseases) and the CDC [95]. The current Clinical Laboratory Improvement Amendments (CLIA)-certified tests available at the CDC for serum or CSF samples are an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin (Ig) M and a microsphere immunoassay (MIA). The CDC also offers a CLIA-licensed plaque reduction neutralization test (PRNT). The PRNT will require biosafety level 3 (BSL-3) facilities, and the turnaround time for testing is 4 weeks according to the CDC [96]. In the older EEEV case report literature, other tests are noted, such as the complement fixation test (CF) and the hemagglutination inhibition test (HI). The CDC does not list any CLIA RT-PCR test as available. 5.2. Molecular Diagnostics Molecular tests are not commercially available; however, publications suggest that nucleic acid detection through RT-PCR may provide a rapid, sensitive approach for acute infections [20,97,98,99]. The disadvantage of this diagnostic method is the limited detection window during the viremic phase (Figure 2B), which is generally between 1 and 3 days post-onset of symptoms but can be up to 7 days in some cases [22,23,25,26,57]. However, molecular diagnostic methods can distinguish between virus species, and this is critical in locations where multiple alphavirus species circulate, such as in Central and South America [20,98,99]. In the 2010 outbreak in Panama, VEEV and MADV cases were being reported, and one patient had VEEV-MADV co-infection. In the same outbreak, it was found that there was a significant amount of IgM cross-reactivity between MADV and VEEV antibodies, and hence, the PRNT, not IgM, was required for an accurate diagnosis [53]. In addition to CSF, serum, and brain samples, MADV RNA was reported in plasma and urine samples of a 12-year-old Venezuelan girl who did not develop encephalitis but had symptoms that were similar to those of dengue and Zika viruses [25]. This finding indicates that urine samples may be useful for detecting MADV/EEEV, as these viruses have a prolonged prodromal phase and IgM results may not yield definitive results in Latin American countries [100]. Metagenomics next-generation sequencing (mNGS) for the identification of arboviruses in patients has been reported [101,102,103,104], including for EEEV [62]. This approach can rapidly distinguish among multiple causative viral species, especially when their disease symptoms overlap, and could provide a turnaround time of 24–48 h. 5.3. Diagnostic Laboratory Tests for Blood and CSF In addition to identification of the etiological agent, a number of diagnostic laboratory tests for blood samples are run to evaluate complete blood count (CBC) and blood chemistry and to evaluate CSF for electrolytes (e.g., sodium), cytological tests (white blood cells and red blood cell counts), glucose, and protein levels. Hyponatremia (serum sodium < 135 mEq/L) has been reported in several EEEV case reports [10,47,60]; however, this has not been reported for any of the MADV case reports we reviewed (Table 1). In a study of 36 EEEV patients, 60% had hyponatremia, and the severity of this correlated with severe outcomes [10]. In that same study, leukocytosis was also predictive of poor outcome in 10/13 patients who had initial cerebrospinal fluid white cell counts of at least 500 cells per cubic millimeter [10]. Leukocytosis has also been reported for MADV patients [20]. Given that patients infected with either virus have elevated white blood cell counts, this stands as a critical test for these patient populations [10,20,44]. Similarly, numerous case studies have reported that EEEV patients exhibit CSF pleocytosis (Figure 2C), often with elevated neutrophil counts early in illness [10,54,57,61,62]. An increase in lymphocytic cells has also been reported [44,89]. As might be expected with high WBC counts, protein levels have been reported to be high in the CSF for some EEEV and MADV patients [10,20,44,57,89]. Lastly, case reports are not clear on glucose levels for EEEV/MADV cases, as some patients’ glucose levels were reduced [35] while others were increased in the CSF [11], but most cases have reported normal CSF glucose levels [10,11,41,46,49]. 5.4. Neurodiagnostic Assessments Clinical practice guidelines by the Infectious Disease Society recommend MRI in all patients with encephalitis and CT if MRI is not available [105]. Imaging using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scanning is not typically recommended [105]. Generally, neuroimaging with MRI and CT shows that EEEV and MADV cases have focal lesions in the basal ganglia, thalami, and brain stem early in the course of disease [105]. In metanalyses of EEEV patients with both CT and MRI data available, MRI demonstrates greater sensitivity, detecting more abnormalities and providing superior anatomic detail [10,42,105,106]. However, where MRI is not available, CT may help clinicians rule out other potential etiological agents, such as human herpes simplex virus encephalitis (HSE) cases, where focal low-density or hemorrhagic lesions in the frontotemporal regions are common, whereas EEE cases more often show CT findings consistent with diffuse cerebral edema [35,105]. It is important to point out that MRI will not provide a definitive etiologic agent diagnosis, as other neurotropic infectious diseases, such as West Nile virus, St. Louis encephalitis, Murray Valley encephalitis virus, and Japanese encephalitis virus, are similar to those observed in both EEEV and MADV patients [105,106,107]. A review of 36 EEE cases reported in the USA between 1988 and 1994 found that focal lesions in the basal ganglia and thalami were the most prominent on MRI in 71% of patients and on CT in 56% and 25%, respectively [10]. In this study, all comatose patients had an abnormal MRI, and hence, they suggest that a diagnosis of EEEV should be questioned if a comatose patient has a normal MRI. On MRI, T2-FLAIR hyperintensities (brighter areas) in EEE cases were also observed in the basal ganglia, thalami, cortical areas, and the brainstem in all patients studied [10,11,39,41,57]. These hyperintensities on MRI suggest edema, and on FLAIR, they suppress the CSF signal, highlighting this abnormality in the brain. A review of MADV case findings from the 2010 outbreak in Panama suggested that the basal ganglia and thalamic lesions, which are the predominant findings in EEE cases, were not as evident, and that other regions, such as the temporal lobes, were involved [20]. A subsequent study of the MRI findings from one of the cases from the 2010 outbreak, a 9-year-old boy, reported T2-FLAIR hyperintense lesions in the frontal and parietal right hemisphere with bilateral basal ganglia and right thalamic-mesencephalic involvement [43]. In addition to neuroimaging, all patients with cerebral dysfunction should undergo an electroencephalogram (EEG) to identify patients with nonconvulsive seizures. Studies show that EEG findings in EEEV patients can range from normal to focal irritability and to spikes associated with nonconvulsive status epilepticus [11]. EEG results of hospitalized EEE patients often show generalized slowing, rhythmic delta activity, and disorganization of the background EEG signal [10,35,49,89]. Notably, some EEE patients have exhibited periodic lateralizing epileptiform discharges on EEG, a pattern characteristic of HSE [10]. Currently, MADV case reports lack EEG findings in patients despite seizures being common. EEG does not confirm the etiologic agent of the infection [11,105]. Improvement of EEG during hospitalization is suggested to correlate with a good prognosis for patients with viral encephalitis, but severe symptoms do not correlate with the disease [105]. 6. Treatment and Management There are no specific therapeutics or antivirals available for treatment of EEE or MADV cases. Our review of the literature suggests that the major approaches to treatment of EEE or MADV are empiric antimicrobial therapy, immunomodulatory interventions, antiseizure medications, and supportive intensive care. We review each of these areas reported in these papers in the following with the caveat that the details of supportive care are often not well defined or in some cases discussed. In the majority of case reports (Table 3), antibiotics were administered on the day of hospitalization in case of suspected bacterial encephalitis (77%), with ceftriaxone (64%) and vancomycin (43%) commonly reported [37,38,41,42,44,46,47,54,55,56,58,61,62,108]. The antiviral acyclovir was used in 64% of the case reports reviewed (Table 3), and it was typically used at or near the start of hospitalization before etiologic confirmation of herpes virus, as recommended [37,38,41,42,44,46,47,54,55,56,61,108]. Early treatment is critical for the effective treatment of herpes viruses, and therefore, it is recommended that it be initiated in all patients with suspected encephalitis as soon as possible, pending diagnostic results [105,106]. In summary, the majority of case reports suggest that antibiotics and acyclovir were initiated together during hospitalization (Table 4). Corticosteroids and intravenous immunoglobulin (IVIG) were commonly reported as immunomodulatory interventions. Anti-inflammatory medications such as dexamethasone, prednisolone, and methylprednisolone were administered in 55% of case reports and were given at various times during hospitalization depending on disease progression [10,20,37,38,41,44,47,52,56,58,62,108]. IVIG was administered in combination with high-dose methylprednisolone in four of the seven case reports that reported using IVIG [38,44,52,58,62,108]. Antiseizure medications were administered in 46% of the case reports reviewed (Table 4). Lorazepam and levetiracetam, or the combination of the two, were administered in four and seven case reports, respectively [56,58,60,62]. Other antiseizure treatments, such as phenytoin, pentobarbital, and valproic acid, were administered in two case reports each [44,46,55]. About half of patients with EEE and a significant amount of MADV patients experience seizures which were nonconvulsive status epilepticus [20,44,55,109]. This type of seizure is often managed by anti-epileptic drugs, including levetiracetam, valproic acid, and lacosamide, along with continuous EEG monitoring [55,58,62]. In other cases, the seizures were focal tonic seizures with secondary generalized convulsions [10,48,49,62], which are typically managed in the hospital through careful titration of multiple anti-epileptic medications, such as phenytoin, levetiracetam, valproate, phenobarbital, and propofol, along with continuous EEG monitoring to guide therapy and asses seizure control [44,49,55,58,62]. Sedatives and narcotic agents have been administered as supportive therapy to mitigate the excessive ventilatory drive observed in one patient with neurological involvement who exhibited persistent tachypnea despite adequate ventilation [40]. In a second case, propofol and fentanyl were used to sedate the patient [44]. Sedatives are also often used in patients on mechanical ventilation [44,49,58,62], which will be discussed briefly in the following. Mechanical interventions, such as airway support, temperature management, and intracranial pressure monitoring, are common in management of EEE and MADV cases. In some patients who have acute hypoxemic respiratory failure, mechanical interventions are needed to support adequate gas exchange to minimize harm to the lungs; for example, see [40,51,60,62]. Intubation is commonly employed to enable adequate respiration; for example, see [47,49,55,58]. In one case report, passive cooling along with antipyretics was used, and a prophylactic catheter was placed to alleviate the patient’s pain and support ongoing supportive care management [40]. In a second case, intravenous fluids, intubation, and the use of cooling blankets (an Arctic Sun device) were used to reduce the patient’s core temperature [61]. Lastly, intracranial pressure monitoring is often used in management of encephalitis and usually in conjunction with other interventions. For example in one case, interventions included intubation for airway protection, use of an intracranial pressure monitor, placement of an external ventricular device, and plasma exchange [58]. The diuretic mannitol, with 3% sodium chloride, was administered in two case reports to reduce intracranial hypertension [44,46]. Despite hyponatremia being commonly reported in EEE cases (Table 1), reports of only two severe cases discussed management with hypertonic saline [58]. 7. Future Directions and Research Gaps Although reported EEE and MADV case numbers in the USA and Latin America are relatively low [33,69], the overall public health burden is substantial given their morbidity and mortality. This is largely because there are no effective vaccines to prevent or treatments to limit brain infection and neurological damage or to promote recovery for those with short- or long-term neurological sequelae [16,87]. Hence, future research that brings to market vaccines for those living in endemic areas and therapeutics for treatment would have a substantial impact. Secondly, disease management could be improved through rapid diagnostic testing. Potential research directions and gaps in these areas are addressed below; however, it is important to note that effective use of direct-acting viral therapeutics requires accurate and timely diagnostics. Vaccines for disease prevention would benefit those living in endemic regions [110,111,112]. Between 2008 and 2025, five clinical trials in Phase 1 or 2 have been reported for EEEV at ClinicalTrials.gov [111] but none for MADV. All have been completed, except for a Bavarian Nordic Phase 2 Trial (NCT06899802) in healthy adults to test a recombinant MVA-BN-WEV protein-based vaccine with structural proteins E1, E2, E3, and 6K for VEEV, EEEV, and WEEV [113]. The Phase 1 trial of MVA-BN-WEV was completed in 2020, and results showed that the candidate was safe and that the treatment resulted in the production of neutralizing antibodies against all vaccine targets [113]. The safety profile in the Phase 1 clinical trial has led to the initiation of Phase 2 in 2025, which is active, not recruiting. In the three other clinical trials, two other platforms were evaluated: (1) TSI-GSD 104 [114], a formalin-inactivated dried EEEV; and (2) VRC 313, a trivalent virus-like particle of VEEV, EEEV, and WEEV. TSI-GSD 104 completed two Phase 2 trials in 2017 and 2018. TSI-GSD 104 was safe and immunogenic; however, vaccination is limited to at-risk laboratory personnel, and there is currently no plan to license this vaccine [114]. During the Phase 1 assessment, three individuals at the U.S. Army Medical Research Institute of Infectious Diseases were exposed to EEEV and were protected, suggesting the vaccine’s efficacy. VRC 313 completed its Phase 1 trial in 2020, and the results indicated that it was safe and well tolerated and that neutralizing antibodies against all vaccine targets were produced. To our knowledge, mRNA vaccine platforms have not yet been reported for these viruses, and given their success with other viruses, research in this area would be value-added. Antivirals for the treatment of the encephalitic alphaviruses would be of great benefit, as most patients experience neurological symptoms shortly after admission. While several small molecules have been reported for the encephalitic alphaviruses, none have progressed into clinical trials [115,116,117]. Given the large incidence of neurological symptoms, it will be essential to discover and develop new antivirals that cross the blood–brain barrier. Another important research gap is the lack of host-targeting therapeutics to treat the resulting immunopathogenesis of infection or those host responses that support replication [117]. Certainly, future research would benefit from the discovery of small molecules that inhibit replication of VEEV, EEEV, and WEEV, whether they are host-directed or directly acting against the virus itself. As with most human RNA viruses, rapid diagnostic tests and treatments are not available commercially, and diagnostic testing for EEEV in the USA is limited to only a few states and CDC laboratories. In the USA, EEEV is primarily diagnosed by IgM testing followed by PRNT, which has a 4-week turnaround time [11,105]. Similar approaches are used in the confirmatory diagnosis of the MADV in Latin America, which also faces additional challenges with the co-circulation of VEEV [98,118,119,120,121]. As discussed in several case reviews, early IgM testing may result in false negatives or positives, so molecular tests that improve early detection and identification of these pathogens would support care and help rule out other potential causes and unnecessary empiric treatments (e.g., acyclovir, antibiotics). Quantitative RT-PCR of blood for the virus remains challenging given the short viremic window; however, inclusion of the virus in a diagnostic panel that multiplexes for all possible etiologic agents of encephalitis would be a significant technological advance. A retrospective study of diagnostic methods for MADV in Panama from 1961 to 2023 reported that infections were identified (n = 26 [92%]) by ELISA IgM, except for one case, where RT-PCR confirmed the presence of viral RNA in autopsy brain samples [26]. Hence, the utility of the RT-PCR approach as a standard approach is unclear and requires further research. The development of new diagnostic approaches that use metagenomic or targeted NGS of the CSF may provide the sensitivity required to detect these viruses in this fluid. However, given the success of antibody-based diagnostics, lateral flow tests that detect IgM antibodies or viral antigens may represent an improved approach. This type of test would also have obvious advantages in rural health care settings where the vast majority of these cases occur. In addition to improving the speed and sensitivity of current diagnostic testing, this review highlights the importance of implementing laboratory tests for hyponatremia and leukocytosis in suspected cases of encephalitis, both of which correlate with poor outcomes. Generally, case reports and reviews would benefit from including additional information on the symptoms and treatment regimens employed, as well as their outcomes. Lastly, there are no published studies that follow up on patients with long-term neurological sequelae to inform the effectiveness of treatments employed. 8. Conclusions In summary, EEEV infection can result in severe disease with high mortality that typically results in neurological disease, and while studies are limited, many of these cases are associated with long-lasting neurological sequelae. Similarly, MADV causes severe disease, although the mortality is lower but still much higher than most viral infectious diseases. Even less is known about the neurological sequelae in MADV patients. Although no FDA-approved antivirals or vaccines are available yet for the treatment of EEEV or MADV, once antivirals are available, rapid viral-specific diagnosis will be critical given the disease’s rapid progression in the brain. The evaluation of these countermeasures is complicated by the low incidence of these diseases, which renders human clinical trials challenging, and by the overlap in virus species causing encephalitis across regions in Central and South America. The use of animal models might be considered for the efficacy testing and approval of vaccines and treatments under the FDA’s Animal Rule. Animal models will also benefit from the translation of clinical insights from studies of human disease progression and neurological sequelae.